Clinical Trial

Low Dose Radiotherapy Combined With Sintilimab and Chemotherapy as Neoadjuvant Therapy for Stage II-III NSCLC

Name: Low Dose Radiotherapy Combined With Sintilimab and Chemotherapy as Neoadjuvant Therapy for Stage II-III NSCLC — clinical trial record (NCT06714708)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting Phase 2

View on ClinicalTrials.gov →

Summary

To evaluate efficacy and safety of low dose radiotherapy combined with sintilimab and platinum based chemotherapy as neoadjuvant therapy for stage II-III Non-Small Cell Lung Cancer

Protocol Amendment History 1 amendment

This ClinicalTrials.gov record has been amended once since 2024-11-28.

Trial Details

NCT Number	NCT06714708
Lead Sponsor	Anhui Provincial Cancer Hospital
Conditions	NSCLC, Neoadjuvant Immunotherapy, Low Dose Radiotherapy, Sintilimab
Enrollment	86 participants
Start Date	2024-11-20
Primary Completion	2026-12-01 (estimated)
Study Completion	2027-06-01 (estimated)
Updated on ClinicalTrials.gov	2025-02-10